Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Review Article

Dendritic cell vaccination for cancer therapy

A Corrigendum to this article was published on 25 October 2001

Abstract

A growing list of defined tumor-antigens opens the way to antigen specific immunotherapy of cancer. However current approaches are often limited in their potential to induce an effective anti-tumor response. Dendritic cells (DC) are natural adjuvants for the induction of antigen specific T cell response. They have been successfully used in clinical pilot trials to induce tumor specific immunity as well as clinical response in selected patients. Current research focuses on optimization of DC source, choice of antigen, antigen loading, mode of injection, as well as immuno-monitoring. Finally, a variety of immune escape mechanisms are operative at the tumor site and have to be overcome for successful vaccination.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2

Abbreviations

APC:

antigen presenting cell

CTL:

cytotoxic T-lymphocyte

DC:

dendritic cell

DDC:

dermal dendritic cell

DTH:

delayed-type hypersensitivity

FLT-3:

fms-like tyrosine kinase 3

FCS:

fetal calf serum

GM-CSF:

granulocyte/macrophage-colony stimulating factor

HLA:

histocompatibility leukocyte antigen

IFN:

interferon

CR:

complete response

IL:

interleukin

KLH:

keyhole limpet hemocyanin

LC:

Langerhans cell

MHC:

major histocompatibility complex

MoDC:

monocyte derived dendritic cells

MR:

mixed response

PBS:

phosphate-buffered saline

PD:

progressive disease

PR:

partial response

SD:

stable disease

References

  • Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP and Gabrilovich DI. . 2000 Clin. Cancer Res. 6: 1755–1766.

  • Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B and Palucka K. . 2000 Annu. Rev. Immunol. 18: 767–811.

  • Becker Y. . 1993 In Vivo 7: 187–191.

  • Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, Valladeau J, Davoust J, Palucka KA and Banchereau J. . 1999 J. Exp. Med. 190: 1417–1426.

  • Boczkowski D, Nair SK, Nam JH, Lyerly HK and Gilboa E. . 2000 Cancer Res. 60: 1028–1034.

  • Borges L, Miller RE, Jones J, Ariail K, Whitmore J, Fanslow W and Lynch DH. . 1999 J. Immunol. 163: 1289–1297.

  • Bröcker E, Poppema S, Terbrak D, Leij LD, Macher E and Sorg C. . 1982 Immunobiol 162: 333.

  • Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ, Peshwa MV, Pitot HC, Richardson RL, Smits BJ, Sopapan P, Strang G, Valone FH and Vuk-Pavlovic S. . 2000 Clin. Cancer Res. 6: 2175–2182.

  • Caux C, Dezutter-Dambuyant C, Schmitt D and Banchereau J. . 1992 Nature 360: 258–261.

  • Caux C, Vanbervliet B, Massacrier C, Dezuter-Dambuyant C, de Saint-Vis B, Jacquet C, Yoned K, Imamura S, Schmitt D and Banchereau J. . 1996 J. Exp. Med. 184: 695–706.

  • Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A and Colonna M. . 1999 Nat. Med. 5: 919–923.

  • Dranoff G, Jaffe E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D and Mulligan RC. . 1993 Proc. Nat. Acad. Sci. USA 90: 3539–3543.

  • Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, de Boer AJ, Punt CJ, Figdor CG and Adema GJ. . 1999 Cancer Res. 59: 3340–3345.

  • Enk AH, Jonuleit H, Saloga J and Knop J. . 1997 Int. J. Cancer 73: 309–316.

  • Flammand V, Sornasse T, Thielemans K, Demanet C, Leo O, Urbain J and Moser M. . 1993 Dendritic cells in fundamental and clinical immunology. ???. (ed). Plenum Press: New York pp. 611–616.

  • Fong L and Engleman EG. . 2000 Annu. Rev. Immunol. 18: 245–273.

  • Freudenthal PS and Steinman RM. . 1990 Proc. Nat. Acad. Sci. 87: 7698–7702.

  • Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D and Carbone DP. . 1996 Nat. Med. 2: 1096–1103.

  • Grabbe S, Bruvers S, Gallo RL, Knisely TL, Nazareno R and Granstein RD. . 1991 J. Immunol. 146: 3656–3661.

  • Grassi F, Dezutter-Dambuyant C, McIlroy D, Jacquet C, Yoneda K, Imamura S, Boumsell L, Schmitt D, Autran B, Debre P and Hosmalin A. . 1998 J. Leukoc. Biol. 64: 484–493.

  • Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J and Liu YJ. . 1997 J. Exp. Med. 185: 1101–1111.

  • Höltl L, Rieser C, Papesh C, Ramoner R, Bartsch G and Thurnher, M. . 1998 Lancet 352: 1358.

  • Hsu FJ, Benike C, Liles FFTM, Czerwinski D, Taidi B, Engleman EG and Levy R. . 1996 Nat. Med. 2: 52–58.

  • Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT and Mukherji B. . 1996 Cancer Res. 56: 2479–2483.

  • Inaba K, Steinman RM, Witmer-Pack M, Aya H, Inaba M, Sudo T, Wolpe S and Schuler G. . 1992 J. Exp. Med. 175: 1157.

  • Knight SC, Hunt R, Dore C and Medawar PB. . 1985 Proc. Nat. Acad. Sci. USA 82: 4495–4497.

  • Lodge PA, Jones LA, Bader RA, Murphy GP and Salgaller ML. . 2000 Cancer Res. 60: 829–833.

  • Mackensen A, Drager R, Schlesier M, Mertelsmann R and Lindemann A. . 2000a Cancer Immunol. Immunother. 49: 152–156.

  • Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W, Spagnoli GC, Cerundolo V and Lindemann A. . 2000b Int. J. Cancer 86: 385–392.

  • Markowicz S and Engleman EE. . 1990 J. Clin. Invest. 85: 955–961.

  • Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB and et al. 1995 Nat. Med. 1: 1297–1302.

  • Morel S, Levy F, Burlet-Schiltz O, Brasseur F, Probst-Kepper M, Peitrequin AL, Monsarrat B, Van Velthoven R, Cerottini JC, Boon T, Gairin JE and Van den Eynde BJ. . 2000 Immunity 12: 107–117.

  • Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME and Lyerly HK. . 1999 Clin. Cancer Res. 5: 1331–8.

  • Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergin MT, Ozols J, Meehan J and et al. 1995 Proc. Natl. Acad. Sci. USA 92: 8078–8082.

  • Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML and Boynton AL. . 1999 Prostate 38: 73–78.

  • Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J and Gilboa E. . 2000 Nat. Med. 6: 1011–1017.

  • Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G and Schadendorf D. . 1998 Nat. Med. 4: 328–332.

  • Nestle FO, Burg G, Fäh J, Wrone-Smith T and Nickoloff BJ. . 1997 Am. J. Pathol. 150: 641–651.

  • Nestle FO and Nickoloff BJ. . 1994 Dermatol. Clin. 12: 271–282.

  • Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus ET, Davoust J and Palucka KA. . 2000 J. Immunol. 165: 3797–3803.

  • Panelli MC, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg SA and Marincola FM. . 2000 J. Immunother. 23: 487–98.

  • Porgador A and Gilboa E. . 1995 J. Exp. Med. 182: 255–260.

  • Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG and Levy R. . 1999 Blood 93: 2411–2419.

  • Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R and Liu YJ. . 1999 Science 283: 1183–1186.

  • Romani N, Gruner S, Kämpgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM and Schuler G. . 1994 J. Exp. Med. 180: 83–93.

  • Romero P, Cerottini J-C and Waanders GA. . 1998 Mol. Med. Today 4: 305–312.

  • Sallusto F and Lanzavecchia A. . 1994 J. Exp. Med. 179: 1109–1118.

  • Schreurs MW, Eggert AA, Punt CJ, Figdor CG and Adema GJ. . 2000 Crit. Rev. Oncog. 11: 1–17.

  • Shimizu K, Fields RC, Giedlin M and Mule JJ. . 1999 Proc. Natl. Acad. Sci. USA 96: 2268–2273.

  • Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S and Liu YJ. . 1999 Science 284: 1835–1837.

  • Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E and Schuler G. . 1999 J. Exp. Med. 190: 1669–1678.

  • Timmerman JM and Levy R. . 1999 Annu. Rev. Med. 50: 507–529.

  • Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT and Storkus WJ. . 1996 J. Exp. Med. 183: 87–97.

Download references

Acknowledgements

Grants from the Cancer League Zürich, the Swiss Cancer League are gratefully acknowledged. We apologize to all our colleagues whose work was not cited due to space limitations.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Nestle, F. Dendritic cell vaccination for cancer therapy. Oncogene 19, 6673–6679 (2000). https://doi.org/10.1038/sj.onc.1204095

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204095

Keywords

  • melanoma
  • dendritic cells
  • immunotherapy
  • antigen-presenting cells
  • immunointervention

This article is cited by

Search

Quick links